CriticalSystemic antimycotics. Imidazole derivatives×Synthetic opioid, full mu-receptor agonist
Updated · Methodology
Mechanism
Several cytochrome P450 enzymes in the liver metabolise methadone, mainly CYP3A4, CYP2B6, CYP2C19, CYP2C9 and CYP2D6 (methadone label, US Food and Drug Administration, FDA). According to the Spanish methadone summary of product characteristics (SmPC), CYP3A4 inhibitors reduce methadone clearance, and it names azole antifungals, including ketoconazole, among them (methadone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ketoconazole is a strong CYP3A4 inhibitor. The EU ketoconazole SmPC contraindicates methadone because a possible rise in methadone levels increases the risk of serious cardiovascular events, including QT prolongation and torsade de pointes, or of respiratory or central nervous system depression (ketoconazole SmPC, European Medicines Agency, EMA). According to the US methadone label, CYP3A4 inhibitors can raise methadone levels and cause potentially fatal respiratory depression, particularly when the inhibitor is added after a stable methadone dose has been reached (methadone FDA label). Methadone itself prolongs the QT interval. QT prolongation and torsade de pointes have been reported especially at high doses, above 100 mg a day according to the Spanish SmPC and above 200 mg a day according to the US label. In vitro, methadone inhibited cardiac potassium channels (methadone SmPC, AEMPS; methadone label, FDA). Ketoconazole itself can also prolong the QT interval (ketoconazole FDA label).
Symptoms
The main risks are QT prolongation with life-threatening torsade de pointes, and respiratory and central nervous system depression (ketoconazole summary of product characteristics, SmPC, European Medicines Agency, EMA; ketoconazole labels, US Food and Drug Administration, FDA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). The US ketoconazole label lists feeling faint, lightheaded or dizzy and an irregular or fast heartbeat as possible symptoms of QT prolongation (ketoconazole FDA label). Methadone overdose shows as slow and shallow breathing, cyanosis, extreme sleepiness that can progress to stupor and coma, pinpoint pupils, floppy muscles, cold skin and sometimes low blood pressure and a slow pulse. Low blood sugar has also been reported (methadone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, overdose section). The peak respiratory depressant effect of methadone occurs later and lasts longer than its peak analgesic effect (methadone FDA label).
Management
The combination is contraindicated. The EU ketoconazole summary of product characteristics (SmPC) lists methadone among contraindicated drugs. The US labels for ketoconazole tablets name methadone in the boxed warning and in the Contraindications section (ketoconazole SmPC, European Medicines Agency, EMA; ketoconazole labels, US Food and Drug Administration, FDA). The interaction table of the US labels says methadone must not be given with ketoconazole under any circumstances or for up to one week after ketoconazole is stopped (ketoconazole FDA labels). The methadone documents are less strict. The Spanish SmPC lists use of CYP3A4 inhibitors among risk factors for QT prolongation that call for caution with methadone (methadone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label advises considering a lower methadone dose with CYP3A4 inhibitors and monitoring often for respiratory depression and sedation (methadone label, FDA). If ketoconazole is stopped in a person taking methadone, methadone levels may fall and withdrawal symptoms may appear. In that case, the US label advises considering a higher methadone dose (methadone FDA label). Stopping methadone abruptly can cause a withdrawal syndrome, so withdraw methadone gradually (methadone SmPC, AEMPS). The Spanish methadone SmPCs recommend an electrocardiogram (ECG) before treatment, two weeks after the start and before any dose increase (methadone SmPCs, AEMPS). Ketoconazole is contraindicated in documented prolongation of the corrected QT interval (QTc). With ketoconazole, record an ECG before treatment, within the first week and then as clinically indicated (EMA). The contraindication applies to oral ketoconazole, whose tablets are used in the European Union for endogenous Cushing's syndrome (EMA). In adults, plasma ketoconazole was undetectable after the cream was applied to the skin or the gel to the scalp, but measurable after the gel was applied to the whole body. No interaction studies have been done with the cream or the gel (ketoconazole cream and gel SmPCs, AEMPS). For respiratory depression, give an opioid antagonist such as naloxone. Repeat it and monitor closely, because its action is shorter than that of methadone. In people physically dependent on opioids, give it very carefully in lower than usual doses (methadone SmPC, AEMPS; methadone label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Metadona (nº registro 62423), sección 4.5 (2026)– AEMPS, CIMA, nº registro 62423, sección 4.5
- FDA: Ketoconazole tablets (ketoconazole) prescribing information (2025)– FDA, DailyMed setid 6d4be760-c723-4f54-a854-12c61cf91703 (Strides Pharma Science Limited), version 8, revised 12/2025, Boxed Warning, Contraindications, Warnings (incl. QT Prolongation), Precautions: Drug Interactions, Medication Guide
- AEMPS: Ficha técnica: Metadona (Metasedin 40 mg) (nº registro 62423), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 62423, revisión 05/2026, secciones 4.4 y 4.5
- FDA: Ketoconazole Tablets USP 200 mg prescribing information (2026)– FDA label, DailyMed setid 1d598696-c6f3-4b7c-ad73-949d2089df35, revised 08/2026, Contraindications
- EMA: Ficha técnica: Ketoconazol (EU/1/14/965), sección 4.3 (2025)– EMA, Ketoconazole Esteve 200 mg comprimidos (autorización europea por procedimiento centralizado), EU/1/14/965/001, ficha técnica (anexo I), información del producto actualizada el 05.05.2025, secciones 4.1, 4.2, 4.3, 4.4 y 4.5
- FDA: Methadone hydrochloride tablets (methadone) prescribing information (2025)– FDA, DailyMed setid 4a44bde6-c348-4316-b0e0-c24b407cb823 (VistaPharm), versión 17, revisión 12/2025, secciones 5.4, 5.9 y 7
- AEMPS: Ficha técnica: Fungarest 20 mg/g crema (ketoconazol) (nº registro 57595), sección 5.2 (2023)– AEMPS, CIMA, nº registro 57595 (Fungarest 20 mg/g crema, Stada), documento 04/2023 (texto revisado 06/2021), secciones 4.5 y 5.2 (sin concentraciones plasmáticas cuantificables tras uso en la piel de adultos)
- AEMPS: Ficha técnica: Ketoconazol Sandoz 20 mg/g gel (nº registro 66037), sección 5.2 (2023)– AEMPS, CIMA, nº registro 66037 (Sandoz), documento 11/2023 (texto revisado 12/2021), secciones 4.5 y 5.2 (niveles plasmáticos detectados tras aplicación en todo el cuerpo)
- AEMPS: Ficha técnica: Metadona, Eptadone 100 mg solución oral (nº registro 69909), sección 4.4 (2026)– AEMPS, CIMA, nº registro 69909 (Eptadone 100 mg solución oral, L. Molteni & C.), revisión 04/2026, secciones 4.3, 4.4 y 4.5